GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » OPKO Health Inc (NAS:OPK) » Definitions » EBIT

OPKO Health (OPKO Health) EBIT

: $-170.8 Mil (TTM As of Dec. 2023)
View and export this data going back to 1995. Start your Free Trial

OPKO Health's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-69.0 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-170.8 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. OPKO Health's annualized ROC % for the quarter that ended in Dec. 2023 was -14.08%. OPKO Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -149.46%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. OPKO Health's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -15.70%.


OPKO Health EBIT Historical Data

The historical data trend for OPKO Health's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OPKO Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -283.45 70.62 4.86 -379.47 -170.81

OPKO Health Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -98.88 -13.61 -13.17 -74.99 -69.04

Competitive Comparison

For the Diagnostics & Research subindustry, OPKO Health's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OPKO Health EV-to-EBIT Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, OPKO Health's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where OPKO Health's EV-to-EBIT falls into.



OPKO Health EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-170.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OPKO Health  (NAS:OPK) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

OPKO Health's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-276.236 * ( 1 - 8.3% )/( (1800.063 + 1797.253)/ 2 )
=-253.308412/1798.658
=-14.08 %

where

Invested Capital(Q: Sep. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2056.68 - 117.996 - ( 138.621 - max(0, 200.554 - 357.239+138.621))
=1800.063

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2011.698 - 118.564 - ( 95.881 - max(0, 200.052 - 309.476+95.881))
=1797.253

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

OPKO Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-276.164/( ( (122.86 + max(53.324, 0)) + (143.517 + max(49.838, 0)) )/ 2 )
=-276.164/( ( 176.184 + 193.355 )/ 2 )
=-276.164/184.7695
=-149.46 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(117.449 + 68.96 + 23.153) - (117.996 + 0 + 38.242)
=53.324

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(123.379 + 65.697 + 17.698) - (118.564 + 0 + 38.372)
=49.838

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

OPKO Health's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=-170.814/1087.983
=-15.70 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OPKO Health EBIT Related Terms

Thank you for viewing the detailed overview of OPKO Health's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


OPKO Health (OPKO Health) Business Description

Traded in Other Exchanges
Address
4400 Biscayne Boulevard, Miami, FL, USA, 33137
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a global supply-chain operation and holding company in Ireland. Opko also owns a speciality active pharmaceutical ingredients manufacturer in Israel. The company's bio-reference testing business consists of routine testing and esoteric testing. Routine tests measure various health parameters, such as the functions of the heart, kidney, liver, thyroid, and other organs.
Executives
Frost Phillip Md Et Al 10 percent owner 4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Hsiao Jane Ph D director 4400 BISCAYNE BLVD, MIAMI FL 33137
Gary J. Nabel director, officer: Chief Innovation Officer C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Elias A. Zerhouni director, officer: Vice Chairman and President 2099 PENNSYLVANIA AVENUE, NW 12TH FLOOR, WASHINGTON DC 20006
John A Paganelli director, other: Chairman of the Board OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Steven D Rubin director OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Pfenniger Richard C Jr director 4400 BISCAYNE BLVD., MIAMI FL 33137
Alexis Borisy director C/O COMBINATORX, INCORPORATED, 245 FIRST STREET, 16TH FLOOR, CAMBRIDGE MA 02142
Jon R Cohen director, officer: SVP OPKO; Exec Chairman BRLI C/O OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Prem A Lachman director 4400 BISCAYNE BLVD., MIAMI FL 33137
Roger Md Medel director 1301 CONCORD TERRACE, SUNRISE FL 33323
Rulfo Fernando Hernandez officer: CAO, Treasurer C/O OPKO HEALTH INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Anthony J Japour director 19805 N. CREEK PARKWAY, BOTHELL WA 98011
Robert Scott Fishel director C/O OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Adam Logal officer: Exec.Dir .of Fin., CAO,Treas. OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137